Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birth Dose of GSK's Reduced-antigen-content Pertussis Vaccine
NCT01110044Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Apr 2010
- Primary completion
- Aug 2012
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of GSK-251154 in pertussis, sponsored by GSK. Planned start Apr 2010; status: withdrawn.
02
Drugs
GSK-251154
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT01110044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01110044.